The country of origin of monoclonal antibodies
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, the country of origin of the monoclonal antibodies will be China or Finland, where the monoclonal antibodies are produced during the antibody production stage.
Ruling text
In your letter dated January 9, 2026, you requested a country of origin ruling on monoclonal antibodies. We apologize for the delay as the information was submitted to our laboratory for analysis. You stated that Abbott imports monoclonal antibodies that are used in toxicology tests to detect drugs of abuse in patient samples.
The monoclonal antibodies are produced via two different scientific methods as follows: 1) Hybridoma cell technology 2) Chinese Hamster Ovary (CHO) cell culture medium The hybridoma cell technology method is a three-step production process that includes cell line creation, antibody production and purification. The first step is the creation of the hybridoma cell line in China where the hybridoma cell line is generated by fusing an antibody-producing B lymphocyte with an immortal myeloma cell.
The hybridoma cell line is then cryopreserved in aliquoted vials and stored under liquid nitrogen. The second step involves the antibody production of the monoclonal antibodies that occurs in China or Finland. During this step, the cryopreserved hybridoma cells are thawed and injected into the peritoneal cavity of mice to produce ascites. The hybridoma cells proliferate in vivo and secrete monoclonal antibodies into the ascitic fluid.
The ascites fluid is then harvested from the mice, pooled, and frozen for subsequent purification. The third step involves purification of the monoclonal antibodies in China or Finland. The antibodies are purified using Protein A chromatography, formulated into a buffer solution, filled into polypropylene containers, and shipped frozen to the United States. The CHO cell culture medium method is also a three-step production process that includes cell line creation, antibody production and purification.
The first step is the creation of the CHO cells in China where the CHO cells are genetically engineered to express a specific monoclonal antibody. The CHO cell line is then cryopreserved in aliquoted vials and stored under cryogenic conditions. The second step involves the antibody production of the monoclonal antibodies that occurs in China or Finland. During this step, frozen CHO cells are thawed and inoculated into culture media in shaking flasks.
Nutrients are supplied through a fed-batch process to extend cell viability and antibody productivity. After approximately 14 days, the culture is harvested and clarified by centrifugation to remove cells and debris, yielding antibody containing culture supernatant. The third step involves purification of the monoclonal antibodies in China or Finland.
Monoclonal antibodies are purified from the clarified culture supernatant using Protein A affinity chromatography, formulated into a buffer solution, filled into polypropylene containers and shipped frozen to the United States. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N357684).